Randox named as Company of the year

Home - Randox

Randox named as Company of the year

Randox tops the charts in Belfast Telegraph Top 100 Companies

Randox is the largest blood-sciences healthcare diagnostics company from the UK and Ireland. Established in 1982 by managing director Dr Peter FitzGerald, Randox manufactures more than four billion tests per year and has a global sales and distribution network supplying product to 145 countries. Randox estimates more than 400 million people, around 5% of the world’s population, receive a diagnosis involving Randox products each year. Key facilities are located at multiple sites within Northern Ireland, in Co Donegal, in West Virginia in the United States and in Bengaluru, India.

As a privately-owned company Randox invests heavily in research and development, committing up to 25% of turnover for the development of new diagnostic products. Recent testing developments include: Type 1 Diabetes Genetic Risk Score; an advanced PSA test to improve the predictive potential of PSA alone for prostate cancer; predictive bladder cancer testing panels; risk assessment for post operative acute kidney injury and chronic kidney disease; and wide-ranging quality control and external quality assurance capabilities to ensure the accuracy and reliability of laboratory results.

Randox’s innovative approach to R&D has allowed the development of allied capabilities outside the immediate world of human healthcare, including leading testing capabilities in the veterinary field, for toxicology and for the detection of harmful drug residues and pathogens in food.

Research and development programmes are not limited to the development of tests, but also includes the advanced analyser systems to process samples efficiently. This requires integral, advanced capabilities in electrical and mechanical engineering, optics, robotics and software engineering.

Over £350m of investment has supported the development of a unique testing system to allow multiple tests to be run simultaneously on a single sample – the Randox Biochip. This 9mm x 9mm platform, which allows up to 49 tests to be run simultaneously, greatly increases the diagnostic power available to clinicians to enable earlier, more accurate diagnosis and improved patient outcomes. Initially focused on proteomics, Randox has also greatly increased its genetic testing capabilities to increase predictive capabilities.

In order to support the model of diagnostically-led healthcare, Randox has developed the Randox Health brand, to provide public access to comprehensive testing. The aim is to empower the consumer and to enable a preventative approach to healthcare – rather than rely upon the treatment of illness. Well over 20 clinics are now available across the UK and Ireland, including in partnership within John Lewis stores.

At the outset of the Covid-19 pandemic Randox was ideally placed to support the UK’s requirement for a national Covid-19 testing programme. By mid-February 2020 Randox were amongst the global frontrunners in developing a Covid-19 test and had developed home sample collection and reporting capabilities. The company was engaged by Government from mid-March 2020 to support the UK’s national testing programme – at that time the complete NHS testing capability for Covid-19 was reported as 2,400 tests per day.

Rising to meet this unprecedented national demand markedly increased company turnover and profits. A post-pandemic assessment by consultants OCO Global concluded that Randox’s activities during the pandemic averted over 3,100 deaths, prevented 14,100 hospitalizations and enabled a £8.3bn contribution to the UK’s GDP.

Exiting from the pandemic and reverting to sector norms with a strong balance sheet, Randox is investing heavily in upgrading the company’s infrastructure and R&D programmes. Randox is also investing significant resources in expanding the business-to-consumer diagnostic offer under the Randox Health brand – with clinics in the UK and Ireland, and US.

Noting the pressures upon all healthcare systems, and a need to transition from ‘illness management’ to more sustainable ‘prevention’ models, Randox is investing heavily for the future. Its aim is to ensure it is well positioned to support and enable healthcare transformation through improved diagnostics, to both increase system efficiencies and improve patient outcomes.


Joe Kennedy III, US special envoy for economic affairs visited Randox Science Park in Antrim last week to listen for presentations on Randox Laboratories MultiSTAT and RABTA analysers. He wrote in a foreword to the Belfast Telegraph article, “I congratulate everyone who has contributed to the success of Northern Ireland’s Top 100 Companies. “From globally-recognised brands to indigenous firms, each company reflects the wide diversity of employers who generate prosperity and opportunity right across Northern Ireland.”

Randox managing director Dr. Peter FitzGerald said it welcomed the accolade of being named number one company.

“These results reflect the skills, commitment and agility of our people, and the capability of our unique technologies.

“As a team we were also able to call upon 40 years of diagnostic experience to meet the exceptional demands of Covid-19, while simultaneously supporting our established global customer base of healthcare laboratories. Crucial to this was our long term commitment to research and development which has always been a cornerstone of our business philosophy.

“Randox is committed to enhancing healthcare through more sensitive and accurate diagnostics to enable the prevention of disease and improve healthcare outcomes, whilst reducing the burden on healthcare services.

“Our profits will continue to be directed towards enabling our infrastructure and research and development, as well as accelerating better healthcare models and improving direct public access through our Randox Health clinics. Our ambition is to enable better health outcomes for all and we are committed to that goal.”

PCR rapid tests for Candida auris for Vivalytic by Bosch now available


World’s first fully automated PCR test for detection of the multidrug-resistant fungus at the point of care. 

  • Vivalytic test detects Candida auris in under an hour at the point of care, making it the world’s first test suitable for screenings.
  • Candida auris infection rates are on the rise in Germany and can cause severe infections, for example in the bloodstream (sepsis).
  • Hospitals can use the new screening test to detect colonization, allowing them to implement measures to contain outbreaks.
Bosch Healthcare solutions has developed a PCR test for detecting Candida auris (C. auris) and on the Vivalytic platform. The test is a global innovation now available for order from distribution partners including Randox Laboratories Ltd. and R-Biopharm. This test enables the fully automated detection of the frequently multi-resistant fungus in less than an hour at the point of care. The rapid testing capability also makes it suitable for carrying out screenings when necessary. In contrast, traditional culture tests in centralized laboratories require one to three days, delaying diagnosis and the initiation of targeted treatment. “Considering the heightened risk of severe progression in individuals with pre-existing conditions, we have developed a new test that enables clinics to respond more swiftly,” states Marc Meier, managing director of Bosch Healthcare Solutions. Patients with compromised immune systems, such as those in intensive care, individuals with serious underlying conditions such as diabetes, or those who are immunosuppressed due to cancer or HIV, as well as patients about to undergo invasive surgery, face a heightened risk of active infection with C. auris. The mortality rate for C. auris infections ranges from 30 to 72 percent.
Candida auris  can be transmitted from person to person through contact and contaminated surfaces. When this fungus presents, rapid detection is therefore rapid detection is therefore paramount to enable implementation of effective control and prevention strategies,” says Dr. med. Alexander Maximillian Aldejohann,  deputy head of the Würzburg Laboratory at the National Reference Center for Invasive Fungal Infections (NRZMyk.) Since July 2023, Germany has implemented a limited statutory reporting requirement under the Infection Protection Act. Aldejohann is in favor of extending this reporting obligation: “The fungus has the capacity to rapidly develop resistance to many common antifungal agents coupled with the ability to survive for a relatively long time on surfaces. This high so-called tenacity also increases the risk of outbreaks that are difficult to contain.”

Increasing spread of Candida auris

C. auris is spreading globally. In some states in the U.S, the annual incidence rate has been shown to increase by a factor of 2 to 3. The Robert Koch Institute (RKI) also drew attention to a rise in cases within Germany during the past year in the Epidemiological Bulletin at the at the beginning of May. The RKI points out that in specific areas screening could be beneficial. In the U.S, the annual case count has in the meantime reached the thousands. The Centres for Disease Control and Prevention (CDC) already consider the screening of patients, visitors, and staff for C. auris as a crucial strategy to curb its spread in healthcare settings. While the fungus is harmless for healthy individuals, it can it can lead to severe nosocomial infections, i.e. infections acquired in hospitals or other healthcare environments, in patients at high risk and, if the fungus enters the bloodstream, can trigger sepsis.
Easy handling, rapid detection The Vivalytic Analyser enables effortless testing directly at the point of care: The sample is placed into the test cartridge, which already contains all necessary reagents. The cartridge is then inserted into the Vivalytic Analyser for automated processing. Healthcare professionals require only minimal training to use the system, and the fully automated process significantly lowers the risk of infection. The Vivalytic Analyser thus facilitates rapid and precise diagnostics in PCR quality, bypassing the frequently lengthy process through a central laboratory. Bosch Healthcare Solutions is expecting CE certification for the Vivalytic C. auris test soon.


For More Information Please Contact:
Martin Conway, Phone: +44 (0) 28 9442 2413
E-mail: martin.conway@randox.co



Dementia Action Week 2024

Dementia Action Week 2024 (13th – 20th May)

The term Dementia describes the different brain disorders that trigger a loss of brain function. These conditions are all usually progressive and eventually severe. Alzheimer’s Disease is the most common type of dementia, affecting 62 per cent of all those diagnosed.

Dementia is a general term for loss of memory, language, problem-solving and other thinking abilities that are severe enough to interfere with daily life.  Common symptoms include memory loss, confusion, and speech problems. Early warning signs may also include finding it difficult to follow conversations, or programs on TV, forgetting names of friends, or everyday objects and feeling confused even in a familiar environment.

Mainly affecting older people, after the age of 65, the likelihood of developing dementia roughly doubles every five years – however, for some dementia can develop earlier, presenting different issues for the person affected, their carer and their family. There is also a considerable economic cost associated with the disease estimated at £23 billion a year, which is predicted to triple by 2040. This is more than the cost of cancer, heart disease, and stroke.

At Randox, we recognise the importance in diagnosing dementia early.  Through our Randox  Alzheimer’s Disease Array which can be used for Rapid Identification of Alzheimer’s Disease Risk. Randox’s Alzheimer’s Disease Risk Array can be used for the direct determination of ApoE4 status from plasma, eliminating the need for genetic testing, assisting in clinical research and personalised medicine strategies. At Randox, we believe the importance of measuring ApoE4 protein expression in plasma is the way forward to screen those individuals at increased risk of Alzheimer Disease, as new beta amyloid-targeting therapies for this condition are being expected.

Race Against Dementia have been the partner charity for the Randox Grand National Festival over the past two years, working alongside this charity which was founded by three-times Formula One World Champion, Sir Jackie Stewart, with the aim of funding much needed pioneering research into the prevention and cure of dementia.

For further information about the Randox Alzheimer’s Array please email info@randoxbiosciences.com

Growth through medical technology: Randox and Bosch invest heavily in the Vivalytic analysis platform

  • New partnership for Vivalytic analysis platform: Bosch and Randox

  • Laboratories Ltd. to invest 150 million euros in research, development, and

  • distribution

  • Strategic growth field: point-of-care molecular diagnostics expected to

  • become a future market worth billions

  • Growth with fully automated laboratory diagnostics: the two companies aim to

  • achieve sales in the nine-figure range by 2030.

  • Smartphone-sized laboratory: sepsis IVD grade test based on cutting-edge

  • BioMEMS technology is a joint development objective.

With many diseases, every minute counts, and determining whether a patient is presenting the symptoms of a simple cold, the flu, or something as severe as life-threatening meningitis is usually only possible after time-consuming and expensive
laboratory diagnostics. With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the
market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company. The two companies will invest around 150 million euros in joint research, development, and sales activities for new tests for the Vivalytic analysis platform provided by Bosch Healthcare. One goal is the development of  a sepsis IVD1 grade test that will be the first to feature highly innovative and novel BioMEMS technology.

Bosch has defined medical technology as a strategic growth field. Point-of-care molecular diagnostics is expected to become a future market worth billions. And with its Vivalytic analysis platform, Bosch aims to achieve a leading position in this market. “With cutting-edge technology from our own labs and our own production lines, we want to grow long-term together with partners in the field of precision diagnostics,” says Stefan Hartung, chairman of the Bosch board of management. “Here, our medical technology can draw considerable benefit from our diversification, from our expertise, from the groundwork we have done in automation, miniaturization, molecular diagnostics, and from our experience in microchip development and manufacturing,” Hartung adds. “We are investing long-term in an exciting high-tech growth field and continuously developing it together with partners. With technology ‘Invented for life’, we can relieve the burden on medical professionals and help make the diagnose and treatment of disease faster”.

Shared growth: decentralized diagnostics at the point of care

Bosch Healthcare Solutions and Randox are now joining forces in an attempt to accelerate the development and market launch of new tests and to make distribution channels more efficient. The partnership is set to run for more than ten years. With Vivalytic, the two companies aim to achieve sales in the medium nine-figure range by 2030. “Globally, healthcare is moving toward decentralized and personalized diagnostics, that enable rapid interventions and individual treatment plans,” says Marc Meier, managing director of Bosch Healthcare
Solutions GmbH. “With our partner Randox, we want to further expand the test portfolio of our Vivalytic analysis device. Our fully automated molecular diagnostics PCR tests provide clarity directly at the site of sample collection,
shorten waiting times, and take the strain off the healthcare system,” Meier adds. The two partners are a good fit: Bosch can contribute its technology and manufacturing expertise across the fields of molecular diagnostics, microchip
development and manufacturing, and miniaturization. The universal Vivalytic platform for molecular diagnostics was developed in over ten years by Bosch researchers and brought to market maturity by Bosch Healthcare Solutions. Randox has 40 years of experience in the design and development of highly sensitive IVD tests performed on a variety of technologies, including microfluidic platforms. In combination with the company’s extensive market knowledge and global sales and distribution network, this adds up to considerable opportunities for growth. “Randox has always been committed to improving health worldwide and sees the need to invest in research and development initiatives that will support clinical decision making across a variety of disease areas. Diagnostics has always been an indispensable component of healthcare, and the alignment of both science and technology makes for the perfect fit in an area for high potential impact, especially in pressure-driven environments,” says Dr. Peter Fitzgerald, Managing Director of Randox Laboratories Ltd. Bosch Healthcare Solutions and Randox already collaborated during the Covid-19 pandemic. In spring 2020, Bosch launched one of the world’s first fully automated PCR tests for the SARS-CoV-2 coronavirus. Together with Randox, the rapid test for use in doctor’s offices, nursing homes, testing stations, and hospitals was made ready for the Vivalytic analysis device within the space of just a few weeks.

Development goal: sepsis test based on BioMEMS technology

One focus of the development partnership with Randox is the implementation of a highly sensitive multiplex2test for sepsis on the Vivalytic analysis platform.Sepsis, also known as “blood poisoning,” is a potentially life-threatening complication3 that can occur in conjunction with various infectious diseases. A medical emergency that can lead to multiple organ failure, it requires immediate medical treatment. The planned IVD grade sepsis test is to be based for the first time on the highly innovative and novel BioMEMS technology developed by teams from Bosch corporate research in Renningen and Bosch Healthcare Solutions in Waiblingen. “We have set ourselves the ambitious goal
of adding the functions of a high-performance silicon chip based on microsystems technology to our test cartridges for the Vivalytic platform. In doing so, we will combine Bosch’s unique expertise in the areas of MEMS chips, molecular diagnostics, and microfluidics,” Marc Meier says. “Clinical outcomes in sepsis depend on timely diagnosis and appropriate early therapeutic intervention. Current methods of sepsis diagnosis are insufficient and time-consuming. With over 10 years of experience in the field of infectious diseases diagnostics, we aim to develop a state-of-the-art sepsis test using the highly multiplexing BioMEMS technology. Such a test could revolutionize sepsis diagnosis, ultimately leading to improved treatment outcomes and lower mortality rates from this life-threatening condition,” says Dr. Peter Fitzgerald.

Smaller and faster: from microfluidics to nanofluidics – thanks to BioMEMS

The powerful BioMEMS chip adds a further innovative analysis method to the Vivalytic test cartridge, enabling it to test simultaneously and significantly faster for a large number of different pathogens. It is called BioMEMS because it combines microelectromechanical systems (MEMS) with microfluidics for applications in the field of medical technology. In microfluidics, very small amounts of fluid in the microliter range are moved in a very small space. Miniaturization allows qualitative biochemical polymerase chain reactions (PCR) to run in parallel in real-time on a single BioMEMS chip. “Compared to previous PCR reactions, the volumes of liquids are reduced by a factor of 1,000 to the nanoliter range. The analysis of liquids is left to a small microchip,” Marc Meier explains. With the new BioMEMS technology, fully automatic testing up to 250 genetic characteristics4 (e.g. pathogens) in one cartridge is possible in less
than 15 minutes. The test cartridge is a highly complex laboratory the size of a smartphone, so to speak. Another future advantage of BioMEMS will be simpler and faster adaptation of new tests or existing tests on the chip itself. For example, existing tests can easily be expanded to include additional features. “The BioMEMS technology paves the way for us to move into nanofluidics, where each pathogen will be examined in a reaction vessel the thickness of a hair,” Meier says. To achieve this, Bosch wants to create more capacity on a MEMS chip and expand it what are known as “nanocavities”. Thanks to t

hese very small cavities, even more biochemical processes will be able to run in parallel on a
chip. With increasing miniaturization, the technology has potential to be used in oncology as well over the long term. The BioMEMS chips are to be manufactured at the Bosch semiconductor plant in Reutlingen, with bio-integration and cartridge
assembly to be carried out at Bosch Healthcare Solutions in Waiblingen.

Vivalytic platform: easy application at the point of sample collection

The advantages of carrying out PCR tests on the Bosch Vivalytic platform lie not only in speedy a

nalysis, but also in the ease of use: Once the sample has been taken, it is placed in the test cartridge. The cartridge, which contains all the necessary reagents for the respective test, is then inserted into the Vivalytic analyser for automated evaluation. Medical staff require only brief training on how to operate it. This enables fast and targeted diagnostics directly at the point of sample collection – either at the doctor’s office or in the hospital – without the often long and time-consuming detour via a central laboratory. Bosch Healthcare Solutions already distributes various tests for diseases of the upper and lower respiratory tract, such as SARS-CoV-2 – also a pooling variant and as a saliva test – or a test to differentiate between SARS-CoV-2, RSV virus and influenza. There are also tests for pathogens that cause sexually transmitted infections (STI) and MRSA / SA (“hospital germ”). Starting in summer, it is planned to expand the portfolio with tests for whooping cough (Bordetella holmesii, Bordetella parapertus

sis, and Bordetella bronchiseptica), urinary tract infections (UTI), bacterial meningitis, the two most common sexually transmitted diseases (Chlamydia trachomatis; CT and Neisseria gonorrhoeae; (NG), fungal infections (Candida auris), and three tests for diarrheal diseases
(norovirus, Clostridioides difficile, HSP)

Contact persons for press inquiries:

Robert Bosch GmbH
Dörthe Warnk, Phone: +49 711 811-55508
E-mail: doerthe.warnk@bosch.com

Randox Laboratories Ltd.

Martin Conway, Phone: +44 (0) 28 9442 2413
E-mail: martin.conway@randox.com


Secretary of State visit to Randox Science Park

The Rt Hon Chris Heaton-Harris, Secretary of State for Northern Ireland paid a visit to Randox Science Park on Thursday, October 19th, to discuss Randox capabilities and undertake a tour of the facilities at the Antrim site.

As leading diagnostic company from the UK & Ireland, Randox have spent over forty years improving healthcare,  with a focus on the provision of timely and accurate  testing both to improve clinical diagnosis and promote preventative healthcare.

The purpose-built facilities at the site, covering research and development, engineering, manufacturing and accredited laboratories provides an unparalleled depth of diagnostic capability with a single site.

More than 5% of the world’s population (over 400 million people) receive medical diagnosis using Randox products each year.

Randox’s proprietary Biochip Technology is the result of a £350 million investment, allowing many tests to be run simultaneously, greatly improving the diagnostic power available to clinicians. This innovative technology allowed the provision of advanced health  profiling to support both early diagnosis and the transition to preventative healthcare.

Randox Science Park is a central hub of Randox’s life science manufacturing, engineering and research and development. Randox employ over 2,200 staff, including 800 research scientists and

engineers – all focused on improving life science diagnostic capabilities globally.

Randox Science Park is one of four key manufacturing and development sites, with others located in Dungloe, County Donegal; Bangalore, India; and the Greater Washington DC area, USA. Across the UK & Ireland there is also a growing network of Randox Health Clinics.



Effortless Data Management: Acusera 24.7 Reports

You’ve carried out your daily maintenance and run your IQC. You’ve got your results and now it’s time to type them up into one of your expansive spreadsheets. Reports

You’ve probably got your spreadsheet set up to calculate the required parameters already, but what if there’s an error in the formula? Or what if you make an error when entering your data? Or worse, what if you try to open the spreadsheet only to find that the file is corrupted or lost? If your Excel file is there, someone else might already be editing it, meaning you must wait until they’re finished before you can make any changes.

Even if you face none of these obstacles the labour-intensive statistics needed for performance review and validation might just keep you up at night.

Well, with Acusera 24.7, these concerns are history.

Whether you make use of our automated or semi-automated data entry options, you can be sure that the data put into the system is exactly that returned by your instrument. If you use the manual data entry option, we can’t remove the human error element – but with our simple and intuitive interface, we trust you’ll be flawless anyway. What’s more, the cloud-based nature of our software also means you won’t lose the data by mistake and unique access for each user allows multiple people to be logged in at the same time.


So, what next?

Well, you can view this data on our dashboard for fast and easy access to your results but delve a little deeper into Acusera 24.7 and you can access comprehensive, easy-to-read, customisable, reports designed to speed up the review process.

These reports include statistical analysis, exception reports, peer group statistics, uncertainty of measurement and advanced statistical metrics. The latter two we’ll look at in a dedicated article. For the others, however, let’s dive in and see how you could benefit from our range of extensive reports.

Statistical Analysis Reports

The first report we will look at is the statistical analysis report. This report allows you to view your IQC data from a specified date range, and compare it to your cumulative data, that is, all the IQC data you’ve collected since you began using that lot, as well as the peer group data for the same lot all within one screen. If you are part of a chain of laboratories, you can compare this data with your laboratory group to see how your lab stacks up by using the World/Group toggle button.

This report provides you with the count, mean, SD, CV, SDI and CVI for a lot and can be organised by assay, as shown in the image below, instrument, or method, allowing you full freedom to customise this report to suit your needs. Don’t forget, like all our reports and charts, this data is fully exportable to PDF or Excel for filing or data review.

Handy, right? This report provides you with everything you need to carry out the validation and verification of new IQC lots, plus much more. We’ll look at this in more detail in an upcoming article.

Exception Reports

If you wish to determine your best and worst-performing tests, our exception report is perfect for you. This report is designed to quickly and easily identify assays with a high percentage of errors. The exception report provides an on-screen summary of the number of QC results for each individual assay and control lot that fall within the following categories: <2SD, 2-3SD and >3SD. This comprehensive performance review can be filtered: by clicking on the top of the ‘>3DSI’ column, this report will display assays in descending order with your worst-performing assays at the top, as shown below.

Filtering by ‘<2SDI’, it will display the same data with your best-performing assays at the top.

With this information, you can determine in which of your assay’s failures most often occur and encourage staff to look a little more closely at why failures arise and identify changes to improve and minimise errors.

Peer Group Statistics Reports

Now that you have figured out the performance of your assays, you’ll want to see how you compare with others running the same tests. Our Peer Group Statistics Report is your new best friend.

Updated live and in real-time, with no submission deadlines, you can compare your statistics to those of your peer group, determined by analyte, method, instrument manufacturer and model.

Simply select the IQC lot you wish to analyse and Acusera 24.7 will generate the data for you, displaying the count of QC data, mean, SD and CV, giving you comprehensive insight into your performance vs your peers.

You can customise this report even further. If you select an analyte, we’ll show you the data for that analyte alone. If not, we’ll show you the information for all analytes related to that lot. The same goes for specifying a date range – if you choose a range, we’ll show you the data inside that range alone. If not, we’ll show you all the data for your chosen lot.

By clicking on the headers, you can filter the data – 1 click will display the data in ascending order, 2 will show you a list in descending order and 3 clicks will reset the table.

When these reports are combined with the other impressive features of Acusera 24.7, like our fully customisable charts or advanced statistical analysis, this software can help streamline your IQC procedure and data review process.

When the accreditors come knocking, others will be scuffling around trying to gather multitudes of reports and files, but you will be sitting with a smile on your face and your feet up, because you’ve got Acusera 24.7.

With full onboarding assistance and technical support that’s top-of-the-class, you’ll always have someone to help you get to the bottom of any problems that you face.

If you haven’t already booked a demo, get in touch with us today and let us show you how much time we can save you with this innovative and intuitive software. Alternatively, take a look at our Resource Hub for some material on Acusera 24.7 or Acusera IQC.

To streamline your QC Data analysis, get in touch with us at marketing@randox.com. 

Acute Kidney Injury and Antimicrobial Stewardship

Acute Kidney Injury and Antimicrobial Stewardship

An estimated 1 in 5 hospital admissions in the UK is associated with acute kidney injury1, providing a clear illustration of the need for novel, rapid detection methods. Our latest whitepaper looks at this common condition and the links between Acute Kidney Injury and Antimicrobial Stewardship. For more details on the things discussed in this article, you can download the full whitepaper below.

Download Whitepaper

Acute Kidney Injury

Acute Kidney Injury is defined as a sudden loss of kidney function. This causes a disruption in the kidneys’ ability to filter waste out of your blood resulting in an accumulation of waste products as well as other imbalances.

The loss of kidney function is the result of a sudden reduction in glomerular filtration rate (GFR), the process through which waste is extracted from the blood and is often reversible2.

Aetiology of Acute Kidney Injury

The differential pressure existing between the glomerulus and Bowman’s is the driving mechanism for glomerular filtration2. This pressure contrast is influenced by the combined resistances of the afferent (leading to the glomerulus) and efferent (leading away from the glomerulus) vascular pathways in the kidney. Under normal kidney function, these resistances are in equilibrium, facilitating the proper functioning of the GFR. For example, an increase in efferent resistance restricts the blood flow out of the kidney, elevating pressure inside the kidney and reducing GFR, and vice versa2. However, in AKI, the decline in renal blood flow and GFR has a pathological origin. The pathophysiology of AKI can be classified as prerenal, intrinsic renal, or postrenal.

The ultrafiltration process in the kidney. Glomerular Filtration Rate. Acute Kidney Injury.
This diagram shows the process of ultrafiltration in the kidney. Blood enters the glomerulus through the afferent arteriole. Blood pressure in the glomerulus is high, causing water and dissolved substances to filter out the blood in the glomerular capillaries, across the Bowman’s capsule and into the renal tubules. The resulting fluid is called the glomerular filtrate. This filtrate then undergoes further modification through reabsorption and secretion, before finally being excreted as urine.

Pre-renal Acute Kidney Injury

Pre-renal AKI is caused by reduced afferent blood flow or, in other words, increased afferent resistance. While tubular and glomerular functions generally remain intact, pre-renal AKI may be caused by systemic hypoperfusion (decreased blood flow) or selective hypoperfusion to the kidney, caused by renal artery stenosis or aortic dissection3.

Intrinsic Renal Acute Kidney Injury

Renal AKI describes the conditions which affect the glomerulus or tubule, for example, acute tubular necrosis and acute interstitial nephritis. This collection of conditions is associated with vasoconstrictor expression in renal afferent pathways2.

Post-renal Acute Kidney Injury

Post-renal AKI usually results from an obstruction in the filtration system. Causes of obstruction include kidney stones, tumours, or blood clots, commonly in the bladder outlet. Obstruction affecting one side might not invariably lead to acute kidney injury, especially when the impediment develops slowly, such as with tumour growth. This is because the unaffected kidney might be able to adjust and make up for the compromised functionality3

Symptoms & Treatment

AKI often manifests with decreased urine output as its primary symptom. However, additional symptoms, when present, can encompass fatigue, nausea, vomiting, or confusion4. To achieve an accurate diagnosis, a comprehensive review of the patient’s medical history and a physical examination are essential to identify the underlying cause of the condition.

The treatment and management of AKI are contingent upon the root cause of the condition. In milder cases, measures are implemented to maintain appropriate levels of fluid, electrolytes, and blood pressure. Nutritional support may also be administered when necessary. In the most severe instances of AKI, dialysis may be warranted to compensate for the diminished kidney function5.

Creatinine serves as a valuable diagnostic tool for evaluating renal conditions, including kidney health, GFR, and muscular dystrophy. However, abnormal serum creatinine (SCr) levels only become evident when a significant portion of the renal mass is compromised. The kidneys possess an impressive capacity to adapt to reduced function, which means that a considerable loss of function or GFR is necessary to influence SCr levels. This poses a challenge when it comes to early detection of AKI6.

Novel biomarkers, KIM-1, NGAL, Clusterin, and Cystatin C, are associated with AKI2 and can be analysed through molecular testing. These new methods can provide a fast and accurate assessment of an individual’s kidney health, at a much earlier stage than SCr quantification2.

Antimicrobial Stewardship

Antimicrobial Stewardship (AMS) programs are specifically crafted to enhance the efficiency of antimicrobial utilization, curtail the emergence of Antimicrobiasl Resistance (AMR), and enhance patient outcomes7. These programs encompass a variety of approaches, such as educational initiatives, training, the establishment of guidelines and protocols, ongoing monitoring and feedback regarding antimicrobial usage, and the management of antimicrobial formularies. Through the promotion of prudent antibiotic utilization, AMS programs contribute to the safeguarding of the efficacy of currently available antimicrobial agents and the deceleration of AMR development7.

Antibiotics and Acute Kidney Injury

Various antibiotics are associated with the progression of AKI due to their nephrotoxicity which can cause severe damage to the kidneys. These antibiotics include polymyxins, aminoglycosides and the commonly used, vancomycin8.

Acute Kidney Injury & Antimicrobial Stewardship

Randox Renal Injury Detection

Using the patented Biochip Technology, the Randox Acute Kidney Injury (AKI) array, available on the Evidence Investigator, simultaneously tests for four novel biomarkers (KIM-1, NGAL, Clusterin, Cystatin C) delivering an early diagnosis and monitoring of treatment efficacy. Multiplex testing better captures reduced renal function, as each biomarker reflects different mechanisms that result in similar injury outputs, allowing for a more accurate picture of the underlying cause of AKI. Along with being able to identify AKI at a much earlier stage, this array provides an accurate and sensitive solution for the diagnosis and monitoring of AKI.

If you’d like some more information on the Randox Acute Kidney Injury Array or would like to add this technology to your laboratory, take a look at our website at https://www.randox.com/acute-kidney-injury/ or get in touch today at marketing@randox.com.


  1. NICE. How common is it? Acute Kidney Injury . Published July 2023. Accessed October 2, 2023. https://cks.nice.org.uk/topics/acute-kidney-injury/background-information/prevalence/
  2. Adiyanti SS, Loho T. Acute Kidney Injury (AKI) Biomarker.; 2012.
  3. Manzoor H, Bhatt H. Prerenal Kidney Failure.; 2023.
  4. NHS. Acute Kidney Injury. NHS. Published 2023. Accessed July 31, 2023. https://www.nhs.uk/conditions/acute-kidney-injury/
  5. Goyal A, Daneshpajouhnejad P, Hashmi M, Bashir K. Acute Kidney Injury . In: StatPearls [Internet]. StatPearls Publishing ; 2023.
  6. Rule AD, Lieske JC. The estimated glomerular filtration rate as a test for chronic kidney disease: Problems and solutions. Cleve Clin J Med. 2011;78(3):186-188. doi:10.3949/ccjm.78a.11004
  7. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(9):990-1001. doi:10.1016/S1473-3099(17)30325-0
  8. Clifford KM, Selby AR, Reveles KR, et al. The Risk and Clinical Implications of Antibiotic-Associated Acute Kidney Injury: A Review of the Clinical Data for Agents with Signals from the Food and Drug Administration’s Adverse Event Reporting System (FAERS) Database. Antibiotics. 2022;11(10):1367. doi:10.3390/antibiotics11101367


Charting the Course to Laboratory Excellence

Are you still using spreadsheets for your QC data and Charts?

You’ve been left behind.

But don’t worry!

Your laboratory’s ultimate ally in the quest for precision and excellence has arrived.

Acusera 24.7 is a tool that not only streamlines your QC data but also empowers you with a treasure trove of invaluable charts.

These charts are more than just numbers and lines; they are your secret weapon for troubleshooting, achieving accreditation, and driving continuous process improvement.

Acusera 24.7 doesn’t just offer charts. It offers a symphony of insights at your fingertips. From the precision of interactive Levey-Jennings charts to the competitive edge of performance summary charts for peer group comparison, from the rhythm of weekly mean charts to the clarity of reliable SD histograms – these charts are your compass in the world of quality control.

The best part?

You’re in control.

Tailor these charts to your unique needs, whether you’re dealing with single or multiple analytes, an abundance of QC lots, fixed or variable SDs, or need to pinpoint data within a specific date range.

Join us on a journey through the world of Acusera 24.7’s charts, where data becomes your strategic advantage, and discover why more laboratories are choosing Acusera 24.7 for QC data management every day.

Levey-Jennings Charts

Every laboratorian has seen countless Levey-Jennings charts and for good reason.

These charts are the unsung heroes of quality control in the laboratory.

They offer a visual snapshot of data over time, helping to detect trends, outliers, and systematic errors that might otherwise go unnoticed. Levey-Jennings charts are like the heartbeat monitor of your laboratory, providing real-time insights into the health of your analytical processes.

We’ve taken Levey-Jennings charts to the next level.

Our colourful graphs might look like they belong in a modern art museum, but trust me, they’re more than just eye candy.

Acusera 24.7’s Levey-Jennings charts are like the laboratory’s personal detective, sniffing out anomalies and shifts and making sure your QC data behaves.

Let’s have a look at what you can do with the Acusera 24.7 interactive Levey-Jennings charts.

The screenshot below shows a Levey-Jennings chart for a single analyte, with the date on the X-axis and SD on the Y-axis. On this chart, you can see data points displayed in different colours. Green data points indicate an acceptable result. Orange points show data that has triggered your predefined alert criteria, while red points are those that have broken your set rejection rules.

The lines marked on the chart below represent events that have been recorded. Instrument events such as calibration events or maintenance can be recorded to monitor their effects on your QC, allowing you to quickly see how these events relate to any deviations or improvements in your QC data. For example, after the event labelled ‘Reagent lot change’ you can see a series of alerts and failures. Marking this event on the chart allows for an at-a-glance explanation of this deviation. These events are completely customisable so you can record any relevant information you want!

Finally, data points that appear as a triangle indicate a comment has been added. What text is included in the comment is completely up to you!


The next screenshot below shows a Levey-Jennings chart containing QC data for all the tests included in the Clinical Chemistry Panel.

Acusera 24.7 panels allow you to group related tests together, helping increase the efficiency of your data review.

It looks great, right?

Maybe a little confusing.

The screenshot is perhaps a little deceptive.

When viewing these charts live, you can view the data as a whole, or home in on individual data sets by simply hovering over the data you want to see. You can also selected a deselect datasets at will by clicking on its name in the list below the chart.

The screenshot below shows an example of this.

All the charts we’ve looked at so far have had a fixed 3SD on the Y-axis.

For a more in-depth review of your data, you may wish to expand this axis.

With the click of a button, you can expand the Y-axis to include all your data points. See below for an example.

In some cases, you may wish to view this data displayed as ‘% Deviation’.

Again, with the click of a single button, you can convert the Y-axis to show just that, as shown below.

Performance Summary Charts

Peer group comparison of IQC data has a lot of benefits.

Comparing your data with other laboratories that use the same QC lot, instrument, method and more, can help you with troubleshooting and continuous process improvement.

The Acusera 24.7 Performance Summary Charts do all the work for you.

As shown in the screenshot below, these charts display your data and how it compares to your peers including mean, CV, and SD.

You can also view this data in a table to get a more detailed picture of your performance.

Like the Levey-Jennings charts, you can also combine this information for panels or a selection of multiple lots and analytes. You can see an example below:

Weekly Mean Charts

Weekly Mean Charts are one of the new features in our latest software release.

They allow you to view your weekly count of QC results for a specific instrument, assay, or lot.

Below is an example in a bar chart format.

You can also view this data as a line graph, which plots the weekly mean of results from multiple instruments using the same assay and QC lot, allowing a comprehensive overview of your QC data.

Or you can view your weekly means for a range of tests and panels.

Finally, the SD Histograms allow you to view the distribution of your results, for an overview of performance.

When used with Acusera 24.7’s suite of advanced statistical tools and reports, our charts can help you reduce the time you spend investigating non-conformances.

When the dreaded accreditation assessment approaches, you can relax. While others are scrambling to find documentation, you can rest assured that all the QC data you need is easily accessible.

Assessors love to see Acusera 24.7 load when they enter a laboratory because they understand how much easier QC management is when using our software.

We provide complete onboarding assistance and full training on the software for new customers while delivering prompt and effective customer support for existing users. The Acusera 24.7 and QC operations teams are always eager to help new and existing Acusera 24.7 users with any issues they experience.

To learn more about the features of this ground-breaking software, visit our website here.

Alternatively, feel free to reach out to us at marketing@randox.com for more information or to arrange a demo!

From Fear to Freedom: A QC Data Management Revolution

What if we told you we had a solution to the multitude of monotonous hours spent analysing reams of IQC data and could provide you with an intuitive tool packed with comprehensive and customisable reports, interactive charts, and automated statistical analysis to help improve your QC data management?

Perhaps it sounds too good to be true?

This time, it isn’t.

Uncertainty of Measurement. 6Sigma. QC Multi-rules. These words can strike fear into the hearts of even the most experienced laboratory staff.

With Acusera 24.7, we’ve reached under the bed and forced the monster that is advanced statistical analysis out into the cold.

Acusera 24.7 is a live, cloud-based, interlaboratory QC data management and peer group comparison software.

A mouthful. I know.

But let’s break it down

A live, cloud-based software means you can access your QC data from anywhere, anytime.

Bid farewell to the labyrinth of folders you hunt through when troubleshooting or looking for a specific dataset.

Interlaboratory management describes the momentous task many QC managers face – monitoring the QC performance of multiple laboratories in different locations, ensuring they all maintain the high standards required for accreditation and accurate patient results.

Unlike some big-name subscription services, we encourage you to use our software at different locations to help you monitor all your laboratories and instruments to see how their results stack up against one another.

Acusera 24.7 provides multiple levels of access which are completely customisable. This allows you to grant or restrict access to different parts of the software depending on what is required by your staff. This also allows QC managers to view data from all their sites in one location without needing multiple email chains from each laboratory.

“24.7 is an invaluable tool to maintain control over 13 sites with multiple platforms and I can’t stress enough how easy it is.”

Peer group comparison? Isn’t that what EQA is for?

Well, you would be right.

Yes, EQA does provide a comparison with your peer group, but it doesn’t have exclusive rights.

There are many benefits to comparing your IQC data with your peer group. The real-time comparison data aids with troubleshooting, or you can show off how great you are to your friends and colleagues.

You can select your peer group for an instrument, method and more, providing you with a comprehensive picture of how your laboratory performance compares to your peers using the same lot of control.

There are no submission deadlines. One less thing for you to worry about.

Still think it sounds too good to be true?

Then let’s look at some of the software features and how they can be used to make your daily QC data management easier.


For many laboratories, review of their QC data is a momentous task involving an abundance of printouts with different data tables and graphs and hastily scribbled notes going back maybe months, if not years.

With Acusera 24.7’s interactive Levey-Jennings charts, you can see the QC data from a specified date range. This helps visualise trends and biases over any period to simplify the troubleshooting and lot validation processes, or, can be used as evidence during accreditation assessments. These charts can be generated for a single analyte or for multiple analytes and QC levels.

You can also add events to the graph to record factors that might impact the performance of your analyser such as preventive maintenance, calibrations or switching QC lots. So, when you come to review the QC data and see a shift in the results, you can see at a glance if there was an explanation for the change in QC results.

What’s more, the points plotted on the chart will appear in orange or red if they trigger your alert or reject protocols respectively. Those that appear as a triangle indicate a comment is attached. Comments can be added to any data point directly on the Levey-Jennings chart, allowing you to record any information relevant to the data, saving you time, not to mention the cost of all those sticky notes.

This complements the Panel feature of the software. Within Acusera 24.7 you can create a panel of tests, for example, a Liver Function Test panel, grouping all the tests together. You can then view all the QC data for this panel at the click of a few buttons. Shown below is the collective data for a clinical chemistry panel.

When you do need the paper copy, all the charts and reports found in Acusera 24.7 can be exported to Excel or PDF for independent analysis or printing, making it easy to bring your data to meetings or for hardcopy filing and audits.

For peer group comparison, you can get a performance summary chart. This chart basically does the analysis for you! You define the date and time range, and the software looks at all the data points within it for you and your peer group, comparing individual data, means, CVs and SDs. Like our other charts, you can combine any number of these for multi-analyte analysis.

Advanced Statistics

Some people love statistics. Others can think of nothing worse.

Either way, there’s a lot of work involved in advanced statistical analysis.

Even if you’re in the love camp, you might find yourself sickened before you’ve finished this metaphorical jar of marmite.

The role of a pathology laboratory is not to run QC and show off their statistical skills, but to provide accurate and appropriate patient results.

As the old saying goes, time is money.

But in your case, time is the difference between a fast or delayed diagnosis for a patient.

This may impact their condition or treatment.

By making use of the suite of statistical options included in Acusera 24.7, including QC Multi-rules, 6Sigma and Uncertainty of Measurement, you can focus on providing the most accurate and efficient testing for patients.

“The software is extremely user-friendly, even the technophobes can use the system quite well.”

Data Entry

To save even more time, Acusera 24.7 can be integrated with many LIMS or Middleware packages for fully automated data transfer.  At a predefined time, your internal software will send your QC data to a shared folder on your network and from there to a Randox Cloud IP address, meaning we don’t go into your IT system and take anything; we won’t cause any information security problems. This data is then taken from the cloud and populated onto 24.7.

All this in less time than it takes you to say, ‘fully automated data transfer.’

You can also import your data through a semi-automated upload procedure. For this, the data is exported from your LIMS or middleware and imported manually to your Acusera 24.7 account using an EDI import file. Simply put, all you have to do is send the file, and the software will populate it onto the system. Alternatively, you can upload the data manually on the simple and intuitive data entry page.

Acusera 24.7, while comprehensive and initially daunting due to its vast array of features, is incredibly easy to use. The Acusera 24.7 and QC operations teams are always eager to help new and existing Acusera 24.7 users with any issues they experience. We provide complete onboarding assistance and full training on the software for new customers while delivering prompt and effective customer support for existing users.

“The correspondence you get from Randox is first-rate.”

We’ve only begun to cover the range of features available on Acusera 24.7 for QC data management! For more information or to arrange a demo, get in touch with our team at marketing@randox.com. Or, you can take a look at our website here. 

“I’ve found working with Randox a productive partnership, both for me personally and for the company.”

IBMS 2023

We will be exhibiting at IBMS 2023!

We invite you to stop by the International Convention Centre (ICC) Birmingham between September 25th and 28th, 2023 for a visit.

Request A Meeting

Biochemistry Stand #301

Join us at stands #301 each day of IBMS 2023 where will be hosting a range of interactive and educational workshops. 

10:00-10:30: Workshop 1 / Acusera 24.7; The worlds most advanced statistical analysis software

11:15-11:45: Workshop 2 / Introducing Third Party Xanthochromia IQC

12:30-13:00: Workshop 3 / Importance of using Serum Indices IQC

14:00-14:30: Workshop 4 / Introducing Third Party Pre-Eclampsia IQC

15:15-15:45: Workshop 5 / Acusera 24.7; The worlds most advanced statistical analysis software

Click the link below to attend!

Attend a Workshop

Meet the Team

Click on the team member’s photo to request a meeting


Barry Maguire

UK Sales Manager






Dipesh Varu

Regional Sales Manager



Dermot Devlin

Business Development, Scotland & Wales




Veena Vara

Sales Executive, North West England



Molecular Stand #302

Randox Molecular Solutions

Join us at stands #302 to discover the full range of Randox Molecular Diagnostic Solutions.


Designed to meet the demand’s of today’s molecular diagnostic laboratory, the Randox range of molecular products comprises; IQC and EQA for molecular infectious disease testing as well as Point of Care, semi and fully automated analysers.  Stop by our booth and discuss Qnostics, QCMD, The Vivalytic, The Discovery and more with our team of specialists.

Request A Meeting

Meet the Team

Click on the team member’s photo to request a meeting


Ben Crawford

Molecular Products,  Manager







Harpreet Singh

Molecular Product Specialist




Craig Ryan

Molecular Product Specialist






Our Portfolio

  • Overview
  • Quality Control
  • The Vivalytic
  • QC Data Management
  • External Quality Assessment

Dedicated to Improving Health Worldwide

With over four decades of experience in the medical diagnostics industry, Randox is dedicated to enhancing global health outcomes. As a provider of high-quality diagnostic solutions, Randox offers a wide range of products and services, including Quality Control, Molecular Diagnostics, Third Party Reagents, Point of Care, and Clinical Chemistry Analysers.

Acusera Quality Controls

Introducing the New Acusera True Third Party Controls. Book a meeting with a Randox QC Specialist today to learn how we can provide you with complete QC solutions for results you can trust.


Molecular Diagnostics at the Point of Care

The all in one molecular solution developed by Bosch and Randox consolidates full molecular workflow into one small benchtop platform. Randox multiplex Biochip Technology powers the Vivalytic enabling multiple results from one patient sample. Click the link below to learn more about the Vivalytic.

ACUSERA 24•7 Interlaboratory Data Management

Discover features such as; Interactive Levey-Jennings Charts, Automatic Calculation for uncertainty of Measurement as well as the Comprehensive Reports generated on demand, with a live demonstration at EuroMedLab.


The world’s largest External Quality Assessment Scheme with more than 55,000 laboratory participants spanning over 134 countries. Choice and flexibility are guaranteed with our 36 programme portfolio, learn more by clicking the button below!

Request a meeting
Make an Enquiry - RX series
Make an Enquiry - Reagents
Kit Insert Request - Reagents